Guoxing Liu
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Research Interests
Guoxing Liu has a total of 40 co-authors. Here are the top co-authors by number of shared publications:
Chengzhi Xie
Division of Hepato-Biliary-Pancreatic Surgery, Department of General Surgery, The Second Xiangya Hospital, Central South University, Changsha, Hunan 410011, China
2 shared publications- Xiaohua Lei
University of South China
2 shared publications - Xundi Xu
Hunan Provincial Key Laboratory of Hepatobiliary Disease Research, Division of Hepato-Biliary-Pancreatic Surgery, Department of Surgery, The 2ndXiangya Hospital, Central South University, Changsha, Hunan Province, 410011, China
2 shared publications - Chengzhi Xie
Hunan Provincial Key Laboratory of Hepatobiliary Disease Research, Division of Hepato-Biliary-Pancreatic Surgery, Department of Surgery, The 2ndXiangya Hospital, Central South University, Changsha, Hunan Province, 410011, China; Department of General Surgery, The Second Affiliated Hospital, Hunan University of Chinese Medicine, Changsha, Hunan Province, 410005, China
1 shared publication Dewu Zhong
Department of Hepato-Biliary-Pancreatic Surgery, The Second Xiangya Hospital, Central South University, Changsha, Hunan 410011, P.R. China
1 shared publication- Dewu Zhong
Hunan Provincial Key Laboratory of Hepatobiliary Disease Research, Division of Hepato-Biliary-Pancreatic Surgery, Department of Surgery, The 2ndXiangya Hospital, Central South University, Changsha, Hunan Province, 410011, China
1 shared publication
Latest Publications
- Open Access
- 1 October 2019
- Published by Elsevier in Biomedicine & Pharmacotherapy
- Vol. 118, 109270
Targeting TRPV1 on cellular plasticity regulated by Ovol 2 and Zeb 1 in hepatocellular carcinoma
- 1 October 2019
- Published by Elsevier in Biomedicine & Pharmacotherapy
- Vol. 118, 109270
Open AccessTargeting TRPV1 on cellular plasticity regulated by Ovol 2 and Zeb 1 in hepatocellular carcinoma
- 1 January 2018
- Published by Elsevier in Life Sciences
- Vol. 192, 91-98
Splenectomy after partial hepatectomy accelerates liver regeneration in mice by promoting tight junction formation via polarity protein Par 3-aPKC
- 1 January 2018
- Published by Elsevier in Life Sciences
- Vol. 192, 91-98
Splenectomy after partial hepatectomy accelerates liver regeneration in mice by promoting tight junction formation via polarity protein Par 3-aPKC
- Open Access
- 11 June 2012
- Published by Spandidos Publications in Oncology Letters
- Vol. 4 (3) , 403-407
Anti-proliferative effects of anandamide in human hepatocellular carcinoma cells
In our previous study, we reported that the cannabinoid receptors CB1 and CB2 are overexpressed in human hepatocellular carcinoma (HCC) tissues. Recently, the antitumor potential of the endogenous cannabinoid anandamide (AEA) has also been addressed. The present study was conducted to investigate the anti-proliferative effects of AEA in HCC cells. The human HCC cell line Huh7 was used. Cell proliferation was measured by MTT assay and flow cytometry. Apoptotic analysis was investigated by TUNEL assay. Real-time PCR and western blot analysis were used to analyze the expression of relevant molecules. The results of this study demonstrated that AEA inhibited the proliferation of Huh7 cells, resulted in G1 cell cycle arrest and induced apoptosis. Furthermore, downregulation of CDK4 and upregulation of p21 and Bak by AEA were observed. This study defines the anti-proliferative effects of anandamide in HCC cells and suggests that AEA has therapeutic potential in the management of HCC patients.
- 11 June 2012
- Published by Spandidos Publications in Oncology Letters
- Vol. 4 (3) , 403-407
Open AccessAnti-proliferative effects of anandamide in human hepatocellular carcinoma cells
In our previous study, we reported that the cannabinoid receptors CB1 and CB2 are overexpressed in human hepatocellular carcinoma (HCC) tissues. Recently, the antitumor potential of the endogenous cannabinoid anandamide (AEA) has also been addressed. The present study was conducted to investigate the anti-proliferative effects of AEA in HCC cells. The human HCC cell line Huh7 was used. Cell proliferation was measured by MTT assay and flow cytometry. Apoptotic analysis was investigated by TUNEL assay. Real-time PCR and western blot analysis were used to analyze the expression of relevant molecules. The results of this study demonstrated that AEA inhibited the proliferation of Huh7 cells, resulted in G1 cell cycle arrest and induced apoptosis. Furthermore, downregulation of CDK4 and upregulation of p21 and Bak by AEA were observed. This study defines the anti-proliferative effects of anandamide in HCC cells and suggests that AEA has therapeutic potential in the management of HCC patients.